GSK Acquires Exclusive Rights for Prostate Cancer Treatment
GSK plc and Syndivia, a private biotechnology company, have announced an agreement granting GSK exclusive worldwide rights to develop and commercialize a preclinical antibody drug conjugate (ADC) for metastatic castration-resistant prostate cancer (mCRPC).
Approximately 1.4 million men worldwide are diagnosed with prostate cancer each year, with around 10-20% developing advanced disease within five years.
For patients with mCRPC, targeted treatment options are limited, and standard care options may be difficult to access and poorly tolerated, resulting in modest efficacy outcomes and low survival rates.
According to the data, the 5-year survival rate for these patients is approximately 30%, with a median survival of around two years.
No direct quote available in the given text.
Author's summary: GSK acquires exclusive rights for a prostate cancer treatment.